@article{oai:nagasaki-u.repo.nii.ac.jp:00002099,
 author = {Takazono, Takahiro and Sawai, Toyomitsu and Tashiro, Masato and Saijo, Tomomi and Yamamoto, Kazuko and Imamura, Yoshifumi and Miyazaki, Taiga and Suyama, Naofumi and Izumikawa, Koichi and Kakeya, Hiroshi and Yanagihara, Katsunori and Mukae, Hiroshi and Kohno, Shigeru},
 issue = {19},
 journal = {Internal Medicine},
 month = {Oct},
 note = {A 35-year-old non-HIV patient developed pulmonary cryptococcosis after the initiation of infliximab. He recovered by fluconazole treatment and completed the therapy for a total of 6 months. However, he experienced a relapse 16 months later during retreatment with infliximab, revealing an interesting clinical course contradicting retreatment. This case also represents the first case of relapsed pulmonary cryptococcosis suspected during treatment with a biologic agent. Both of these aspects generated important clinical questions about the length of pulmonary cryptococcosis treatment and the necessity of introducing a second prophylaxis for such patients., Internal Medicine, 55(19), pp.2877-2880; 2016},
 pages = {2877--2880},
 title = {Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment},
 volume = {55},
 year = {2016}
}